Lauren Feldman 6/16/2023 at 5:35 pm
Labiotech (June 16, 2023) Can ChatGPT be used to advance drug discovery?
Chat GPT – which is a large language model (LLM) and belongs to a family of artificial intelligence (AI) known as generative AI – has been a revelation for many people around the world, and, since its launch, has been used by professionals in many industries to assist with work-related tasks, such as editing and writing code. But can it also be used in the life sciences industry to advance drug discovery?
Physicians Committee for Responsible Medicine (June 15, 2023) House Committee Passes FDA Funding Bill, Supports Nonanimal Testing Methods
This week, the U.S. House Appropriations Committee voted to advance the Fiscal Year 2024 (FY24) funding bill and committee report for the Food and Drug Administration (FDA). The bill report includes several provisions supported by the Physicians Committee to advance progress for the wider acceptance of nonanimal methods. Nonanimal approaches, including modern in vitro and computational innovations, rely on human cells, tissues, and data to improve safety and efficacy of medical product development, and increase efficiency by cutting down on resource-intensive animal testing. The Physicians Committee appreciates the House Appropriations Committee including these provisions in the bill’s report to helpboth protect animals and improve FDA-regulated product testing.
This week, Bill S-5 was passed by the Senate and given royal assent. It includes language that brings Canada closer to “modernized toxicity testing,” according to a Windsor researcher who helped shape the legislation. Charu Chandrasekera says laboratories of the future will be forced to turn to other methods to determine whether chemicals are safe — instead of using rats, mice and dogs. For the past four years, Chandrasekera has led the University of Windsor’s Canadian Centre for Alternatives to Animal Methods. Chandrasekera refers to the new law as “landmark legislation” and says Canada is now primed to leap forward into a new era of research and innovation.
Clinical Trials Arena (June 15, 2023) Streamlining healthcare with AI for drug development
Two of the biggest challenges facing healthcare R&D are the sheer volume of data and the unique characteristics of every person’s health. Artificial intelligence (AI) and other technologies offer a way forward. AI for drug development is rapidly streamlining R&D processes, speeding up time to market and providing a better experience for patients and providers. Learn more about the role of AI in drug development and how healthcare researchers are using it to shake up the field.
Technology Networks (June 13, 2023) Handheld Bioprinter That Prints Personalised Tissues and Organs
A new handheld device can print biocompatible structures in situ, with the potential to revolutionize how physicians treat damaged tissue and organs. In situ bioprinting, which involves 3D printing biocompatible structures and tissues directly within the body, has seen steady progress over the past few years. In a recent study, a team of researchers developed a handheld bioprinter that addresses key limitations of previous designs, i.e., the ability to print multiple materials and control the physicochemical properties of printed tissues. This device will pave the way for a wide variety of applications in regenerative medicine, drug development and testing, and custom orthotics and prosthetics.
Science Direct (June 6, 2023) Epithelial-Stromal Interactions in Barrett’s Esophagus Modeled in Human Organ Chips
Barrett’s esophagus (BE) is an adaptive response of the lower esophagus to recurring exposure to gastroesophageal reflux that leads to intestinal metaplasia and/or gastric metaplasia depending on the specific criteria in each country.1 The tissue microenvironment and local resident fibroblasts are critically involved in tissue homeostasis and repair processes2; however, the involvement of stromal-derived fibroblasts in BE and, in particular, their involvement in rare instances of metaplastic transformation and progression to esophageal adenocarcinoma (EAC) are poorly understood.
Nature Medicine (June 1, 2023) Researchers and regulators plan for a future without lab animals
The US Food and Drug Administration has reduced requirements for preclinical animal testing, leading to a surge of interest in organoids, tissue chips and in silico testing.
- You must be logged in to reply to this topic.